3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
47
Neutropenia
26
Lymphoma
25
Lymphoma, Non-Hodgkin
12
Lymphoma, Large B-Cell, Diffuse
12
Neoplasms
11
Sarcoma
9
Lymphoma, Follicular
9
Ovarian Neoplasms
8
Lymphoma, Mantle-Cell
8
Leukemia
8
Hodgkin Disease
8
Carcinoma, Non-Small-Cell Lung
8
Lung Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Triple Negative Breast Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Multiple Myeloma
5
Lymphoma, B-Cell, Marginal Zone
5
Chemotherapy-induced Neutropenia
5
Rhabdomyosarcoma
4
Neoplasm Metastasis
4
Lymphoma, Large-Cell, Immunoblastic
4
Burkitt Lymphoma
4
Waldenstrom Macroglobulinemia
3
Urinary Bladder Neoplasms
3
Testicular Neoplasms
3
Sarcoma, Synovial
3
Prostatic Neoplasms
3
Neurofibrosarcoma
3
Interventions
Paclitaxel
5
Etoposide
4
Oxaliplatin
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Cyclophosphamide
3
Cisplatin
3
Carboplatin
3
ribociclib
2
fludarabine
2
etoposide phosphate
2
Stem Cell Transplantation
2
Sirolimus
2
Melphalan
2
Filgrastim
2
Everolimus
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
tozuleristide
1
sonidegib
1
ripretinib
1
pralsetinib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
olaparib
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled